Home > Boards > US Listed > Biotechs > Synthetic Biologics, Inc. (SYN)

The Lancet is a great journal. She has

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Seel Member Profile
 
Followed By 73
Posts 1,904
Boards Moderated 0
Alias Born 04/30/11
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/29/2021 7:07:27 AM
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial PR Newswire (US) - 6/29/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2021 7:05:44 AM
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards PR Newswire (US) - 5/26/2021 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2021 6:05:43 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2021 5:31:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2021 4:16:23 PM
Synthetic Biologics reports Q1 results Seeking Alpha - 5/5/2021 4:16:06 PM
Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results PR Newswire (US) - 5/5/2021 4:10:00 PM
Synthetic Biologics files for $300M mixed shelf offering Seeking Alpha - 5/3/2021 5:28:59 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/3/2021 4:52:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/3/2021 4:46:10 PM
Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 PR Newswire (US) - 4/28/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/14/2021 7:02:21 AM
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematop... PR Newswire (US) - 4/14/2021 7:00:00 AM
Dosing underway in Synthetic Bio's early-stage SYN-020 study in intestinal alkaline phosphatase Seeking Alpha - 4/1/2021 7:44:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2021 7:01:55 AM
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphat... PR Newswire (US) - 4/1/2021 7:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/4/2021 4:47:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/4/2021 4:16:33 PM
Synthetic Biologics EPS misses by $0.10 Seeking Alpha - 3/4/2021 4:14:05 PM
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results PR Newswire (US) - 3/4/2021 4:10:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/2/2021 3:34:07 PM
Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021 PR Newswire (US) - 2/25/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/22/2021 9:46:18 AM
Seel   Friday, 11/20/15 02:51:48 PM
Re: dodger0328 post# 6576
Post # of 8288 
The Lancet is a great journal. She has published there before. Doesn't look like we'll get the MRI results that the trimesta investors want so much though - at least that is my interpretation of this statement from the UCLA MS page:
"In our recently completed multicenter trial of estriol in women with MS where we found significant beneficial effects on relapses and cognition, we acquired brain MRI scans. These MRI scans now need to be assessed for which region of the brain estriol treatment had the greatest effect impact on halting gray matter atrophy and with correlation to improvement in each disability."

I do like this statement: "A trial focusing on whether estriol treatment can improve cognition in not only RRMS, but also in progressive MS is needed. We have begun that trial, and it is ongoing at 4 sites across the U.S. Based on our results in the relapse trial, we know that this new trial is on target with regard to its optimal design and outcomes. In this trial, estriol treatment can be added on to other standard of care MS treatments (not just Copaxone, but also interferons or the new orals) or estriol can be used in people on no other MS treatments. The treatment duration is one year, and the primary outcome is cognitive testing."

And this statement makes me consider the possibility that the write up may show more positives for cognition than for RRMS - which is not in anyway a negative in the long term. The cognition trial is structured and active and they have a ton of data to support positive outcome. But...since the published study goals were RRMS based, SYN could be pummeled. "An unfortunate likelihood is that a treatment that optimally preserves or repairs leg strength may be different from a treatment that optimally preserves or repairs cognitive ability, which may, in turn, be different from one for vision. It is unlikely that there will be a silver bullet treatment to repair all disabilities in MS. The “one size fits all” approach is untenable given the known differences in neurological pathways."

Who knows? I don't. Could be a seriously positive response or could give bashers opportunity to pummel. But if SYN is in for a beating, the pain will be short lived. The cognition trial currently underway is the most positive path for Trimesta. When it is done - there will likely be lots of celebrating and lots of green accounts.

http://neurology.ucla.edu/clinic/programs/multiple-sclerosis

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences